Browsing ICR Divisions by author "Bliss, Judith"
Now showing items 61-80 of 106
-
Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.
Gao, Q; López-Knowles, E; Cheang, MCU; Morden, J; Ribas, R; et al. (BMC, 2019-12-31)BACKGROUND: Endocrine therapy reduces breast cancer mortality by 40%, but resistance remains a major clinical problem. In this study, we sought to investigate the impact of aromatase inhibitor (AI) therapy on gene expression ... -
Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor-positive Breast Cancers.
Bergamino, MA; Morani, G; Parker, J; Schuster, EF; Leal, MF; et al. (AMER ASSOC CANCER RESEARCH, 2022-03-15)PURPOSE: Aromatase inhibitor (AI) treatment is the standard of care for postmenopausal women with primary estrogen receptor-positive breast cancer. The impact of duration of neoadjuvant endocrine therapy (NET) on molecular ... -
Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation.
Gellert, P; Segal, CV; Gao, Q; López-Knowles, E; Martin, L-A; et al. (NATURE PORTFOLIO, 2016-11-09)Pre-surgical studies allow study of the relationship between mutations and response of oestrogen receptor-positive (ER+) breast cancer to aromatase inhibitors (AIs) but have been limited to small biopsies. Here in phase I ... -
Implementation of platform trials in the COVID-19 pandemic: A rapid review.
Vanderbeek, AM; Bliss, JM; Yin, Z; Yap, C (ELSEVIER SCIENCE INC, 2022-01-01)MOTIVATION: Platform designs - master protocols that allow for new treatment arms to be added over time - have gained considerable attention in recent years. Between 2001 and 2019, 16 platform trials were initiated globally. ... -
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), (ELSEVIER SCIENCE INC, 2019-04-06)BACKGROUND: Increasing the dose intensity of cytotoxic therapy by shortening the intervals between cycles, or by giving individual drugs sequentially at full dose rather than in lower-dose concurrent treatment schedules, ... -
Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727).
Tovey, H; Sipos, O; Parker, JS; Hoadley, KA; Quist, J; et al. (AMER ASSOC CANCER RESEARCH, 2023-09-15)PURPOSE: The TNT trial (NCT00532727) showed no evidence of carboplatin superiority over docetaxel in metastatic triple-negative breast cancer (mTNBC), but carboplatin benefit was observed in the germline BRCA1/2 mutation ... -
Is breast seroma after tumour resection associated with patient-reported breast appearance change following radiotherapy? Results from the IMPORT HIGH (CRUK/06/003) trial.
Bhattacharya, IS; Haviland, JS; Perotti, C; Eaton, D; Gulliford, S; et al. (ELSEVIER IRELAND LTD, 2019-07)BACKGROUND: Seroma describes a collection of serous fluid within a cavity, occurring following surgery. Seroma is associated with normal tissue effects (NTE) following breast radiotherapy, as reported by clinicians and on ... -
It's PRIMETIME. Postoperative Avoidance of Radiotherapy: Biomarker Selection of Women at Very Low Risk of Local Recurrence.
Kirwan, CC; Coles, CE; Bliss, J; PRIMETIME Protocol Working Group; PRIMETIME Protocol Working Group (2016-09) -
Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials.
Haviland, JS; Mannino, M; Griffin, C; Porta, N; Sydenham, M; et al. (ELSEVIER IRELAND LTD, 2018-01-01)BACKGROUND AND PURPOSE: Adjuvant lymphatic radiotherapy (LNRT) is recommended for selected axillary node positive women with early breast cancer. We investigated whether hypofractionated LNRT is safe combined with ... -
Long-Term Follow-Up of the Intergroup Exemestane Study.
Morden, JP; Alvarez, I; Bertelli, G; Coates, AS; Coleman, R; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2017-08-01)Purpose The Intergroup Exemestane Study, an investigator-led study of 4,724 postmenopausal patients with early breast cancer (clinical trial information: ISRCTN11883920), has previously demonstrated that a switch from ... -
Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial.
Smith, I; Robertson, J; Kilburn, L; Wilcox, M; Evans, A; et al. (ELSEVIER SCIENCE INC, 2020-11-01)BACKGROUND: Preoperative and perioperative aromatase inhibitor (POAI) therapy has the potential to improve outcomes in women with operable oestrogen receptor-positive primary breast cancer. It has also been suggested that ... -
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), (ELSEVIER SCIENCE INC, 2018-01-01)BACKGROUND: Neoadjuvant chemotherapy (NACT) for early breast cancer can make breast-conserving surgery more feasible and might be more likely to eradicate micrometastatic disease than might the same chemotherapy given after ... -
Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast Cancer.
Gao, Q; López-Knowles, E; U Cheang, MC; Morden, J; Ribas, R; et al. (OXFORD UNIV PRESS, 2018-05-22)To investigate the impact of sampling methodology on gene expression data from primary estrogen receptor-positive (ER+) breast cancer biopsies, global gene expression was measured in core-cut biopsies at baseline and surgery ... -
Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies.
Robertson, JFR; Di Leo, A; Johnston, S; Chia, S; Bliss, JM; et al. (NATURE PORTFOLIO, 2021-02-12)Endocrine therapy (ET) is recommended as first-line therapy for the majority of patients with hormone receptor-positive (HR+), human epidermal growth factor 2-negative advanced breast cancer (ABC); however, the efficacy ... -
Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers.
Schuster, EF; Lopez-Knowles, E; Alataki, A; Zabaglo, L; Folkerd, E; et al. (NATURE PORTFOLIO, 2023-07-07)Aromatase inhibitors (AIs) reduce recurrences and mortality in postmenopausal patients with oestrogen receptor positive (ER+) breast cancer (BC), but >20% of patients will eventually relapse. Given the limited understanding ... -
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial
Larkin, J; Marais, R; Porta, N; de Castro, DG; Parsons, L; et al. (CELL PRESS, 2024-03-19) -
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.
Larkin, J; Marais, R; Porta, N; Gonzalez de Castro, D; Parsons, L; et al. (Elsevier BV, 2024-03-19)Mucosal (MM) and acral melanomas (AM) are rare melanoma subtypes of unmet clinical need; 15%-20% harbor KIT mutations potentially targeted by small-molecule inhibitors, but none yet approved in melanoma. This multicenter, ... -
Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010).
Ring, A; Kilburn, LS; Pearson, A; Moretti, L; Afshari-Mehr, A; et al. (AMER ASSOC CANCER RESEARCH, 2023-12-01)PURPOSE: Approximately 10% to 15% of triple-negative breast cancers (TNBC) have deleterious mutations in BRCA1 and BRCA2 and may benefit from PARP inhibitor treatment. PARP inhibitors may also increase exogenous replication ... -
Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer.
Snowdon, C; Kernaghan, S; Moretti, L; Turner, NC; Ring, A; et al. (BMC, 2022-05-07)BACKGROUND: Platform trial designs are used increasingly in cancer clinical research and are considered an efficient model for evaluating multiple compounds within a single disease or disease subtype. However, these trial ... -
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Geyer, CE; Garber, JE; Gelber, RD; Yothers, G; Taboada, M; et al. (ELSEVIER, 2022-10-10)BACKGROUND: The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or ...